Life sciences company Avacta Therapeutics (AIM:AVCT) on Thursday reported new preclinical data showing that its investigational cancer drug AVA6207 overcame resistance to topoisomerase I inhibitors (TOP1i) in laboratory studies and animal models.
The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, on 19 November 2026.
AVA6207 uses Avacta's pre|CISION technology to deliver two therapeutic payloads, exatecan and the ATR inhibitor berzosertib, directly to tumours through a single tumour-specific cleavage event. The combination is designed to prevent cancer cells from repairing DNA damage, potentially overcoming treatment resistance.
Preclinical studies demonstrated activity in tumours associated with SLFN11 loss and ATM deficiency, two mechanisms linked to increased dependence on ATR signalling. ATM-deficient cells showed approximately tenfold greater sensitivity to AVA6207 than ATM-positive cells, while the candidate reversed TOP1i resistance in SLFN11-deficient cells.
In patient-derived xenograft models, AVA6207 achieved complete responses in all animals with ovarian tumours and four of five animals with non-small cell lung cancer (NSCLC). The candidate also demonstrated superior activity to marketed antibody-drug conjugate Enhertu in a gastric cancer model.
Avacta is assessing biomarker-defined patient populations across colorectal, NSCLC, ovarian and oesophageal squamous cell cancers for potential clinical development. The company said payload selection has been completed and AVA6207 is expected to enter IND-enabling studies in the fourth quarter of 2026.
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Sophos IRB and ALCMI partner to support lung cancer research